CDSCO guideline for import drugs in bulk for non-medical uses

The Central Drugs Standard Control Organisation (CDSCO) in India outlines guidelines and procedures for obtaining permission to import drugs in bulk for non-medical uses. This process is managed through the SUGAM portal, an e-governance solution. The guidelines include circulars, annexures detailing required documents, guidance documents, and a user manual for the online system.


Key Points from the Circular

  • Streamlining the Process: CDSCO has streamlined the process for issuing Dual Use No Objection Certificates (NOCs) for drugs imported in bulk for non-medicinal use via the SUGAM portal, enhancing the ease of doing business.
  • One-Year NOCs: To reduce compliance burdens, CDSCO has initiated the issuance of 1-year NOCs, subject to specific conditions for the drugs.
  • Revised Checklist: The SUGAM checklist and related procedures have been revised, and a guidance document is attached.
  • Online Submission: Applications for Dual Use NOCs must be submitted through the SUGAM portal with fresh registration and the prescribed documents.
  • System Functionality: The modified system is now functional on the SUGAM portal.
  • Effective Date: The new online Dual Use system will be live from August 31, 2025.


Annexure Highlights

  • New Registration Start Date: The new registration process will begin on August 5, 2025.
  • Eligibility: From September 1, 2025, only users registered and approved by CDSCO as Dual Use NOC Traders/Actual Manufacturers can apply for Dual Use NOC on the new Sugam portal.
  • Required Documents:
    • Address Proof: A copy of the firm's address proof issued by a government authority, such as:
    • Certificate of Incorporation
    • Form 18
    • GST Certificate
    • INC-22
    • Importer Exporter Code (IEC) Certificate
    • BSNL/MTNL Telephone Bills
    • Undertaking Form: A scanned copy of the filled, stamped, and signed undertaking form.
    • ID Proof of Authorized Person: Valid identification as specified in Point No. 5 of the undertaking form.

Guidance Document Summary

  • Objective: Provides guidance on obtaining permission for importing drugs in bulk for non-medicinal use as per Rule 43 of the Drugs and Cosmetics Rules, 1945.
  • Scope: Covers the regulation of drugs imported for non-medicinal use in industries like pharmaceuticals, food, and animal feed.
  • Purpose: To streamline and ensure compliance in the importation process under Schedule D of the Drugs and Cosmetics Rules.
  • Procedure:
    • Online submission of application for a No Objection Certificate (NOC).
    • Registration on the SUGAM portal.
    • Application for NOC at the zonal/sub-zonal office, followed by procedures for release at the port office.
    • Applicants must register on the SUGAM Portal, selecting the user role as "Dual Use NoC."
    • Application to the concerned zonal/sub-zonal office with all necessary documents for a Dual Use NOC, valid for one year or until the sanctioned amount is exhausted.
    • Filling out Step/Phase II form, obtaining clearance from the port office, and completing the supply chain module.
  • Phase I/Step 1:
  • Registration on the Sugam portal verified by CDSCO HQ.
    • Uploading necessary documents, including undertaking forms, address proof, and ID proof. 
    • Providing details such as Corporate Identification Number (CIN), Custom House Agent (CHA) details, and Importer representative details. 
    • Dual-use NOC validity needs verification by the zonal/sub-zonal office, which may issue it within 7 working days. 
    • Required documents include the Integrated Registration Form (IRF), supporting documents, a legal undertaking on Rs. 100 stamp paper, specific usage details, permissions and justifications, quantity justification, technical literature, reconciliation data, and a declaration by the applicant.

  • Phase-II/Step 2:
    • Procedure for release of consignment at the port office after obtaining a valid Dual Use NOC.
    • Submission of documents, including a covering letter, Certificate of Analysis (CoA), bill of entry details, original label, and purchase invoice.
    • Submission of data for each import in the given online format, verified by the concerned port office.
    • Reconciliation module to be open throughout the NOC validity for repetitive releases.

  • Key Points:
    • Complete application submission required.
    • Apply for dual-use clearance at least two months before import.
    • Items must be clearly labelled with their intended use.
    • Manufacturers must submit a Licensing Authority-attested Master Formula Record.
    • Imports for purification or sterilisation are not eligible.
    • Import permission is valid for one year for actual users.
    • Step 1/Phase-I is done by CDSCO Zonal/Sub Zonal office, and Step 2/Phase-II is done by the Port Office does Step 2/Phase-II.

  • Annexure I & II: Legal undertakings to be submitted by actual users or importers/traders, including declarations about the use and handling of the imported drugs.
  • Guidelines can be found here.
Location: Mumbai, Maharashtra, India

Comments

Post a Comment

Popular posts from this blog

FDA alerts drug manufacturers to the risk of benzene contamination in certain drugs

Image
The FDA is investigating the root cause of benzene contamination in certain drugs and informing drug manufacturers about the risks associated with benzene contamination from drug components and other potential factors. Here's a summary of the FDA's alert to drug manufacturers regarding the risk of benzene contamination in certain drugs: Key Concerns: Benzene Contamination: The FDA is alerting drug manufacturers to the potential risk of benzene contamination in drug products. Benzene is a known human carcinogen. Root Cause Evaluation: The FDA is evaluating the root cause of benzene contamination in certain drugs and alerting drug manufacturers to the risk of benzene contamination from drug components. Recalls: Certain drug products, including hand sanitisers, benzoyl peroxide products, and aerosol drug products, have been recalled due to benzene contamination. Manufacturer Responsibilities: Testing: Drug manufacturers are required to establish scientifically sound and appr...
Read more

The Central Drugs Standard Control Organisation(CDSCO) issued a circular for Nitrosamines in Ranitidine

NDMA, also known as N-Nitrosodimethylamine, and other nitrosamines are significant concerns for the pharmaceutical industry. USFDA and other health agencies, especially in strict regulatory markets (SRM), require nitrosamine risk assessments in the dossiers submitted to the respective authorities.  Many countries have banned the drug products which would have the potential to form nitrosamines during the manufacturing process or storage. Ranitidine is one of them. CDSCO has also recently issued a circular on 12 July 2025. The circular can be found here .  The circular addresses concerns about NDMA impurity in Ranitidine. It informs State/UT Drug Controllers of recommendations from the Drugs Technical Advisory Board (DTAB), following a report by an expert committee.  The DTAB recommends forming a larger committee to examine all aspects of Ranitidine, the ICMR (Indian Council of Medical Research) conducting a safety assessment on NDMA impurity, and manufacturers monitoring ...
Read more

FDA form 483 observations: NATCO Pharma

FDA form 483 observations: NATCO Pharma General Information: • Company: NATCO Pharma Limited, Pharma Division, Kothur Village, Rangareddy,           Telangana, India • Inspection Dates: 06/09/2025 - 06/19/2025 • Products manufactured: Sterile and Non-Sterile Drug Manufacturers   Oral solid dosages, including Cytotoxic Orals Cytotoxic Injectables Pre-filled Syringes Key Observations: 1. Environmental Monitoring Deficiencies (Observation 1): The firm's system for monitoring environmental conditions in aseptic processing areas is deficient. Electronic data for non-viable particle (NVP) counts used in environmental monitoring and cleanroom qualification is not adequately reviewed. Discrepancies exist between electronic data and official hardcopy results for NVP, affecting multiple batches between 11/02/2023 and 04/16/2024, where results were altered. Operators saved data on USB drives, potentially allowing data manipulation, which indicates a gap in dat...
Read more